On November 14, 2023, Celyad Oncology SA closd the transaction. The company issued 14,903,846 shares at an issue price of ?0.52 per share for the gross proceeds of ?7,749,999.92 in second and final tranche.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.335 EUR | +6.35% | -1.33% | -14.10% |
Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.10% | 14.82M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CYAD Stock
- News Celyad Oncology SA
- Celyad Oncology SA announced that it has received ?9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A.